Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Novartis's failed cholesterol drug trial caused Amgen (AMGN) to drop 10% and Eli Lilly (LLY) to fall 2%, impacting the Lp(a) drug class. Amgen's stock is at $394.38, while Novartis (NVS) fell 14% to $137.63. Amgen reported positive Phase 3 results for a lung cancer drug, but the market focused on Lp(a) risks. Citi analysts question the Lp(a) hypothesis, affecting pipeline assets like Amgen's Olpasiran.
How this was made
The 30-second read
Why it matters
The immediate price drops reflect market re‑pricing of cardiovascular‑outcome risk, with broader implications for biotech ETFs and sector sentiment.
Market read
The article highlights a material, same‑day catalyst that reshapes risk perception for the Lp(a) drug class and related equities.
What to watch
Potential for regulatory feedback on Lp(a) trial designs and the impact of upcoming conference presentations.
Background
A failed late‑stage trial for Novartis' pelacarsen triggered a sector‑wide sell‑off in Lp(a) therapeutics, affecting peers Amgen and Eli Lilly.
Ticker impact
Amgen fell 10% after Novartis' failed Lp(a) trial, despite reporting a positive Phase 3 lung cancer result.
Further intraday decline or volatility until clarification on Olpasiran.
Double-digit move driven by competitor failure and class-wide risk reassessment.
Novartis' pelacarsen missed its primary endpoint, causing a 14% drop in NVS shares.
Continued weakness pending further data or strategic response.
First‑report of a major Phase III failure for a large‑cap biotech.
Eli Lilly fell 2% on concerns that its Lp(a) program may be impacted by the same class failure.
Potential further downside if additional Lp(a) candidates miss endpoints.
Price move is secondary to the primary Novartis failure but still news‑driven.
Market effects
The Lp(a) drug class faces heightened scrutiny, likely pressuring all biotech firms with similar programs.
U.S. healthcare sector underperforms the broader market, dragging down related ETFs.
International investors may reassess exposure to cardiovascular‑focused biotech pipelines.
Counterpoint
Amgen's concurrent positive lung‑cancer data could offset long‑term concerns if the company pivots away from Lp(a).
Key entities
- CompanyAmgen
Large‑cap biotech; stock down 10% on same‑day news.
- CompanyNovartis
Swiss pharma; pelacarsen trial failure.
- CompanyEli Lilly
Biotech; modest 2% decline.
